Brief: BBDF And Theranexus Plan To Launch Phase I-III Study With BBDF-101 For Patients With CLN3 Disease
03/03/2021 17:33
March 3 (Reuters) - Beyond Batten Disease Foundation:
* BBDF SAYS BBDF AND THERANEXUS PLAN TO LAUNCH PHASE I-III
STUDY
WITH THE BBDF-101 FOR PATIENTS WITH CLN3 DISEASE IN 2021 IN
TEXAS HOUSTON CHILDREN'S HOSPITAL (TCH)
Source text for Eikon: ID:nPre5BsNra
Further company coverage: ALTHX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease